GAL3ST1 Protein

GAL3ST1 Protein — Cerebroside Sulfotransferase

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea; text-align:center; font-size:1.1em;">GAL3ST1 — Cerebroside Sulfotransferase</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Cerebroside Sulfotransferase (CST)</td></tr>
<tr><td><strong>Gene</strong></td><td>[GAL3ST1](/genes/gal3st1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q04589](https://www.uniprot.org/uniprot/Q04589)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>22q13.33</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~46 kDa (423 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Golgi apparatus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Sulfotransferase family</td></tr>
<tr><td><strong>EC Number</strong></td><td>2.8.2.21</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

GAL3ST1 (Galactose-3-O-Sulfotransferase 1), also known as cerebroside sulfotransferase (CST), is a critical enzyme in the biosynthesis of sulfatides—sulfated galactocerebrosides that are essential components of the myelin sheath. This enzyme catalyzes the final step in sulfatide production, transferring a sulfate group from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to galactocerebroside, converting it to sulfatide (3-O-sulfo-galactosylceramide).

GAL3ST1 Protein — Cerebroside Sulfotransferase

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea; text-align:center; font-size:1.1em;">GAL3ST1 — Cerebroside Sulfotransferase</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Cerebroside Sulfotransferase (CST)</td></tr>
<tr><td><strong>Gene</strong></td><td>[GAL3ST1](/genes/gal3st1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q04589](https://www.uniprot.org/uniprot/Q04589)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>22q13.33</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~46 kDa (423 amino acids)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Golgi apparatus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Sulfotransferase family</td></tr>
<tr><td><strong>EC Number</strong></td><td>2.8.2.21</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

GAL3ST1 (Galactose-3-O-Sulfotransferase 1), also known as cerebroside sulfotransferase (CST), is a critical enzyme in the biosynthesis of sulfatides—sulfated galactocerebrosides that are essential components of the myelin sheath. This enzyme catalyzes the final step in sulfatide production, transferring a sulfate group from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to galactocerebroside, converting it to sulfatide (3-O-sulfo-galactosylceramide).

In the nervous system, GAL3ST1 is absolutely required for normal central and peripheral nervous system myelination. The enzyme is primarily expressed in oligodendrocytes (CNS) and Schwann cells (PNS), where it generates the sulfatides essential for myelin membrane stability and function. GAL3ST1 deficiency causes metachromatic leukodystrophy (MLD), a fatal autosomal recessive demyelinating disorder, while alterations in sulfatide metabolism have been implicated in multiple sclerosis, Alzheimer's disease, and other neurodegenerative conditions [@sulfatide_biosynthesis].

Domain Architecture and Catalytic Mechanism

Protein Structure

GAL3ST1 is a type II transmembrane protein with a characteristic domain organization:

• N-terminal cytosolic tail: Short (15-20 aa) cytosolic domain containing sorting signals
• Transmembrane helix: Single-pass transmembrane domain anchoring the protein in the Golgi membrane
• Stem region: Extended lumenal region connecting TM to catalytic domain
• C-terminal catalytic domain: ~380 aa sulfotransferase domain facing the Golgi lumen

Catalytic Properties

GAL3ST1 exhibits the following enzymatic properties:

| Property | Specification |
|----------|---------------|
| Substrate | Galactocerebroside (GalCer) + PAPS |
| Product | Sulfatide (3-O-sulfo-GalCer) + PAP |
| pH optimum | 6.5-7.5 (Golgi lumen) |
| K_m for GalCer | ~5 μM |
| K_m for PAPS | ~2 μM |
| Localization | Golgi apparatus (cisternal membranes) |

The reaction mechanism involves:

Regulation of GAL3ST1 Activity

GAL3ST1 activity is regulated at multiple levels:

Normal Cellular Functions

Sulfatide Biosynthesis

GAL3ST1 catalyzes the final step in the sulfatide biosynthesis pathway:

Myelin Formation and Maintenance

Sulfatides generated by GAL3ST1 are essential for myelin:

Myelin Membrane Composition

• Sulfatides comprise 5-15% of total myelin lipids (highest in PNS)
• Concentrated in the outer leaflet of myelin membranes
• Enriched at the intraperiod line (non-compact myelin)
• Present at high concentrations at nodes of Ranvier

Structural Functions

• Membrane stability: Sulfate group provides negative charge, enabling electrostatic interactions
• Compaction: Sulfatides participate in myelin compaction
• Protein organization: Interact with myelin proteins (PLP, MBP)
• Water homeostasis: Sulfatide-regulated ion and water balance

Axon-Glia Interactions

Sulfatides mediate critical oligodendrocyte-axon communications:

• Axonal support: Sulfatides promote axonal viability through trophic support
• Node of Ranvier: Proper sulfatide distribution is essential for sodium channel clustering
• Metabolic coupling: Facilitate metabolite exchange between oligodendrocytes and axons
• Axonal transport: Sulfatide deficiency impairs axonal transport machinery

Immune System Functions

GAL3ST1 is expressed in immune cells and modulates immune responses:

• CD1d ligand: Sulfatides are ligands for CD1d on antigen-presenting cells
• NKT cell development: Sulfatide-CD1d interactions influence NKT cell populations
• Macrophage function: Affects phagocytosis and cytokine production
• Autoimmunity: Loss of sulfatides may contribute to autoimmune demyelination

Expression in the Nervous System

Brain Regional Distribution

GAL3ST1 exhibits region-specific expression correlating with white matter:

| Brain Region | Expression Level | Primary Cell Types |
|--------------|------------------|-------------------|
| White matter | Very high | Oligodendrocytes |
| Corpus callosum | High | Oligodendrocytes |
| Cerebellum | High | Oligodendrocytes |
| Brainstem | High | Oligodendrocytes |
| Spinal cord | High | Oligodendrocytes |
| Gray matter | Low | Scattered oligodendrocytes |

Cellular Expression

Oligodendrocytes

• Expression pattern: Highest in mature oligodendrocytes
• Subcellular localization: Golgi apparatus, where sulfatide synthesis occurs
• Developmental regulation: Expression peaks during active myelination (postnatal weeks 2-4 in mouse)
• Lineage: Both pre-myelinating and myelinating oligodendrocytes express GAL3ST1

Schwann Cells (PNS)

• Expression: High in myelinating Schwann cells
• Function: Generates PNS myelin sulfatides
• PNS-CNS differences: Higher sulfatide content in PNS myelin

Other Cell Types

• Astrocytes: Low expression; may contribute to sulfatide turnover
• Neurons: Minimal expression; acquire sulfatides from glial cells
• Microglia: Some expression; role in immune modulation

Role in Neurodegenerative Diseases

Metachromatic Leukodystrophy (MLD)

GAL3ST1 deficiency causes MLD, a paradigmatic demyelinating disorder:

Pathogenesis

• Enzymatic deficiency: Loss of cerebroside sulfotransferase activity
• Substrate accumulation: Galactocerebroside accumulates in oligodendrocytes/Schwann cells
• Product deficiency: Sulfatide deficiency in myelin membranes
• Dual toxicity: Both accumulation and deficiency cause pathology

Clinical Features

• Infantile form: Most common; onset 1-2 years; rapid progression
• Juvenile form: Onset 4-12 years; slower progression
• Adult form: Onset after 12 years; variable; often misdiagnosed

Neuropathology

• Diffuse demyelination throughout CNS and PNS
• Accumulation of galactocerebroside in macrophages
• Progressive white matter degeneration
• Axonal loss in later stages

Multiple Sclerosis

GAL3ST1 and sulfatide metabolism are implicated in MS:

• Demyelination: Sulfatide loss is a hallmark of demyelinating lesions
• Remyelination failure: Failure of oligodendrocyte precursor differentiation may involve sulfatide synthesis defects
• Autoimmunity: Sulfatide-CD1d-NKT cell axis may be relevant to MS pathogenesis [@sulfatide_ms]
• Therapeutic relevance: Enhancing sulfatide synthesis may promote remyelination

Alzheimer's Disease

Emerging evidence links GAL3ST1 to AD:

• Sulfatide alterations: AD brain shows reduced sulfatide levels
• Myelin vulnerability: White matter damage in AD includes sulfatide loss
• Cognitive function: Sulfatide deficiency correlates with cognitive decline [@sulfatide_cognition]
• Amyloid interaction: Sulfatides may modulate amyloid processing

Parkinson's Disease

While primarily a gray matter disorder, PD involves white matter changes:

• Oligodendrocyte dysfunction: GAL3ST1 may be affected in PD
• Myelin alterations: White matter abnormalities in PD
• Iron metabolism: Sulfatide and iron interactions relevant to PD pathogenesis

Interaction with Other Neurodegeneration Pathways

Myelin Pathology

GAL3ST1 sits at the intersection of myelin-related pathways:

• PLP/DM20 metabolism: Sulfatides interact with proteolipid proteins
• MBP interactions: Myelin basic protein associations
• Cholesterol metabolism: Myelin lipid homeostasis
• Oligodendrocyte development: Affects OPC differentiation

Lipid Metabolism

GAL3ST1 connects to broader lipid metabolism:

• Ceramide metabolism: Shares precursors with other ceramide species
• Sphingolipid pathways: Central node in sphingolipid biosynthesis
• Fatty acid metabolism: Palmitate and other fatty acids as precursors
• Cholesterol trafficking: Myelin cholesterol homeostasis

Neuroinflammation

GAL3ST1 affects inflammatory responses:

• Cytokine regulation: Sulfatides modulate microglial activation
• Immune cell trafficking: Affects immune cell infiltration
• Autoimmunity: CD1d-sulfatide-NKT axis in demyelination

Therapeutic Implications

Rationale for Targeting GAL3ST1

Modulating GAL3ST1 has therapeutic potential:

Therapeutic Strategies

| Approach | Status | Notes |
|----------|--------|-------|
| Enzyme replacement | Preclinical | Recombinant GAL3ST1 delivery |
| Gene therapy (AAV) | Preclinical | Target oligodendrocytes |
| Gene therapy (ex vivo) | Clinical trials | Hematopoietic stem cell gene therapy |
| Substrate reduction | Preclinical | Inhibition of galactocerebroside synthesis |
| HSCT | Standard of care | Early treatment for MLD |

The FDA-approved gene therapy Libmeldy (atidarsagene autotemcel) for MLD utilizes ex vivo gene correction of hematopoietic stem cells [@gal3st1_therapeutic].

Challenges

• BBB delivery: Enzyme/gene must reach CNS oligodendrocytes
• Timing: Early intervention before irreversible damage
• Immune response: Anti-enzyme antibodies may develop
• Systemic effects: Enzyme affects multiple tissues

Cross-Linking to Related Topics

GAL3ST1 connects to numerous NeuroWiki pages:

Proteins and Genes

• [GAL3ST1 Gene](/genes/gal3st1) — Encoding gene
• [ARSA (Arylsulfatase A)](/proteins/arsa-protein) — Sulfatide catabolism
• [UGT8](/genes/ugt8) — Galactocerebroside synthesis
• [PLP1](/proteins/plp1-protein) — Major myelin protein
• [MBP](/proteins/mbp-protein) — Myelin basic protein

Mechanisms

• [Sulfatide Metabolism](/mechanisms/sulfatide-metabolism-neurodegeneration) — Pathway overview
• [Sphingolipid Metabolism](/mechanisms/sphingolipid-metabolism) — Lipid class
• [Myelin Biology](/mechanisms/myelin-biology) — Myelin formation
• [Oligodendrocyte Function](/cell-types/oligodendrocytes) — Myelin-producing cells

Diseases

• [Metachromatic Leukodystrophy](/diseases/metachromatic-leukodystrophy) — Primary disease
• [Multiple Sclerosis](/diseases/multiple-sclerosis) — Demyelination
• [Leukodystrophies](/diseases/leukodystrophies) — White matter disorders

See Also

• [GAL3ST1 Gene](/genes/gal3st1)
• [Sulfatide Metabolism in Neurodegeneration](/mechanisms/sulfatide-metabolism-neurodegeneration)
• [Sphingolipid Metabolism](/mechanisms/sphingolipid-metabolism)
• [Myelin Biology](/mechanisms/myelin-biology)
• [Metachromatic Leukodystrophy](/diseases/metachromatic-leukodystrophy)
• [Oligodendrocyte Function](/cell-types/oligodendrocytes)
• [Arylsulfatase A](/proteins/arya-sulfatase-a)

References

External Links

• [UniProt: GAL3ST1 (Q04589)](https://www.uniprot.org/uniprot/Q04589)
• [NCBI Gene: GAL3ST1](https://www.ncbi.nlm.nih.gov/gene/9512)
• [OMIM: GAL3ST1](https://omim.org/entry/604582)
• [AlphaFold: GAL3ST1](https://alphafold.ebi.ac.uk/entry/Q04589)